

**ASX ANNOUNCEMENT**

**4<sup>th</sup> September 2019**

## **Capitol Health announces extension of on-market share buy-back**

Capitol Health Limited (**Capitol** or the **Company**) (ASX: CAJ) refers to the ASX announcement on the 9<sup>th</sup> August 2019 noting the changes to the current on-market share buy-back as part of its ongoing capital management program.

The buy-back has been extended for a period of 12 months because it remains important to Capitol to maintain the maximum amount of flexibility with regard to its capital management strategies to enhance value for shareholders. The maximum number of shares under the buy-back has also increased to 76,844,482, with up to 28,800,438 shares remaining to be bought back during the buy-back period within the '10/12 limit' in the Corporations Act 2001 (Cth).

The ASX announcement on the 9<sup>th</sup> August 2019 inadvertently attached an Appendix 3C instead of an Appendix 3D necessary to change the terms of the existing buy-back. The Company retracts the Appendix 3C lodged on the 9<sup>th</sup> August 2019 and attaches a corrected Appendix 3D.

---

For further information, please contact:

Justin Walter  
CEO  
(03)9348 3333  
[investors@capitolhealth.com.au](mailto:investors@capitolhealth.com.au)

### **About Capitol Health**

Capitol Health is a leading provider of diagnostic imaging and related services to the Australian healthcare market. Headquartered in Melbourne, Victoria, the Company owns and operates clinics throughout Victoria, Tasmania, and Western Australia. The Company's operational focus is on delivering a community-based infrastructure for radiologists and related medical practitioners to deliver optimal, efficient, accurate healthcare service outcomes for patients.

Capitol also has an investment in diagnostic imaging artificial intelligence through Enlitic Inc in the US, and a Joint Venture with CITIC Pharmaceutical (Shenzhen) Co., Ltd ("CITIC Pharmaceutical") to provide consulting and clinic management services across mainland China.

# Appendix 3D

## Changes relating to buy-back (*except* minimum holding buy-back)

*Information and documents given to ASX become ASX's property and may be made public.*

Introduced 1/9/99. Origin: Appendix 7B. Amended 13/3/2000, 30/9/2001, 11/01/10

Name of entity	ABN/ARSN
Capitol Health Limited	117 391 812

We (the entity) give ASX the following information.

1 Date that an Appendix 3C or the last Appendix 3D was given to ASX	18 August 2017 (3C) 4 September 2018 (3D)
---	--

### Information about the change

*Complete each item for which there has been a change and items 9 and 10.*

<b>Column 1</b> (Details announced to market in Appendix 3C or last Appendix 3D)	<b>Column 2</b> (Details of change to buy-back proposals)
---	--

#### On-market buy-back

2 Name of broker who will act on the company's behalf	Taylor Collison Limited	No Change
3 Deleted 30/9/2001.		
4 If the company/trust intends to buy back a maximum number of shares/units – that number  <small>Note: This requires a figure to be included, not a percentage. The reference to a maximum number is to the total number including shares/units already bought back and shares/units remaining to be bought back. If the total has not changed, the item does not need to be completed.</small>	52,300,000	76,844,482

<sup>+</sup> See chapter 19 for defined terms.

**Appendix 3D**  
**Changes relating to buy-back**

---

	<b>Column 1</b> (Details announced to market in Appendix 3C or last Appendix 3D)	<b>Column 2</b> (Details of change to buy-back proposals)
5 If the company/trust intends to buy back a maximum number of shares/units – the number remaining to be bought back	43,658,142	28,800,438
6 If the company/trust intends to buy-back shares/units within a period of time – that period of time; if the company/trust intends that the buy-back be of unlimited duration - that intention	5 September 2018 to 4 September 2019	5 September 2019 to 4 September 2020
7 If the company/trust intends to buy back shares/units if conditions are met – those conditions	N/A	N/A

**All buy-backs**

8 Any other change	N/A	N/A
--------------------	-----	-----

---

<sup>+</sup> See chapter 19 for defined terms.

9 Reason for change	Extension of current on market buy-back and increase to the maximum number of shares to be bought back for ongoing capital management
10 Any other information material to a shareholder's/unitholder's decision whether to accept the offer (eg, details of any proposed takeover bid)	N/A


## Compliance statement

1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.

*or, for trusts only:*

1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here:

  
.....  
(~~Director~~/Company secretary)

Date: 4 September 2019

Print name: Melanie Leydin

== == == == ==

---

<sup>+</sup> See chapter 19 for defined terms.